Daily Stock Analysis, EYEG, EyeGate Pharmaceuticals Inc, priceseries

EyeGate Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
4.50
Close
4.97
High
5.25
Low
4.50
Previous Close
4.50
Daily Price Gain
0.47
YTD High
8.83
YTD High Date
Jan 15, 2019
YTD Low
2.25
YTD Low Date
Aug 20, 2019
YTD Price Change
-2.08
YTD Gain
-29.54%
52 Week High
8.85
52 Week High Date
Nov 19, 2018
52 Week Low
2.25
52 Week Low Date
Aug 20, 2019
52 Week Price Change
-1.48
52 Week Gain
-22.99%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 1. 2017
15.30
Sep 18. 2017
17.42
10 Trading Days
13.86%
Link
LONG
Nov 3. 2017
17.11
Nov 7. 2017
18.31
2 Trading Days
6.97%
Link
LONG
Apr 16. 2018
6.00
May 1. 2018
7.89
11 Trading Days
31.51%
Link
LONG
Oct 2. 2018
6.30
Oct 5. 2018
6.81
3 Trading Days
8.10%
Link
LONG
Nov 15. 2018
7.12
Nov 28. 2018
7.48
8 Trading Days
5.00%
Link
LONG
Jan 14. 2019
7.88
Jan 16. 2019
8.29
2 Trading Days
5.24%
Link
LONG
Jun 19. 2019
3.77
Jun 21. 2019
3.97
2 Trading Days
5.38%
Link
LONG
Aug 28. 2019
2.79
Aug 30. 2019
2.97
2 Trading Days
6.45%
Link
LONG
Sep 17. 2019
3.67
Sep 18. 2019
3.93
1 Trading Days
7.08%
Link
LONG
Oct 30. 2019
3.30
Nov 7. 2019
3.76
6 Trading Days
13.98%
Link
Company Information
Stock Symbol
EYEG
Exchange
NasdaqCM
Company URL
http://www.eyegatepharma.com
Company Phone
781-788-9043
CEO
Stephen From
Headquarters
Massachusetts
Business Address
271 WAVERLEY OAKS ROAD, SUITE 108, WALTHAM, MA 02452
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001372514
About

EyeGate Pharma is a clinical stage pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. Its products include EGP-437 and EyeGate II Delivery System. EGP-437 for the treatment of non-infectious anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris or ciliary body. The EyeGate II Delivery System features a compact, elegant, and easy-to-use device that delivers drugs non-invasively and quickly into the ocular tissues through the use of iontophoresis, which can accelerate the onset of action, dramatically reduce treatment frequency versus eye drops and sustain therapeutic effect. The company was founded in 1998 and is headquartered in Waltham, MA.

Description

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye. The company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. It is also developing the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial defects, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. In addition, the company is developing Eyegate II drug delivery system. It has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.